ESSA Pharma (NASDAQ:EPIX) Releases Earnings Results, Misses Expectations By $0.01 EPS

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) issued its quarterly earnings data on Tuesday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01), Zacks reports.

ESSA Pharma Stock Down 1.8 %

NASDAQ:EPIX opened at $1.66 on Tuesday. The business’s 50-day moving average price is $1.72 and its 200 day moving average price is $3.70. ESSA Pharma has a 52-week low of $1.40 and a 52-week high of $10.94.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EPIX. Jefferies Financial Group cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Oppenheimer cut shares of ESSA Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th. Finally, Piper Sandler lowered ESSA Pharma from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $15.00 to $2.00 in a report on Monday, November 4th.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.